Adapted from Schmidt et al. (2015) and Krych-Goldberg et al. (2002). The ectodomain of CR1 is composed of 30 Complement Control Protein (CCP) domains which are organized into four ‘Long Homologous …
(A) Shows the global frequencies of the Sl alleles. Sl1 is represented in blue and Sl2 in red. (B) Shows the global frequencies of the McC alleles. McCa is represented in green and McCb in purple. …
Forest plot showing the associations between Sl and McC polymorphisms and severe malaria in Kilifi, Kenya. Filled boxes: adjusted Odds Ratios (aOR) for the Sl2 genotype in the recessive form (i.e. Sl…
Interaction plots showing the interaction between Sl (recessive) and α+thalassaemia for the proportion of children suffering (A) cerebral malaria and (B) death. For α+thalassaemia status, 0 = wild …
Geometric mean parasite densities in the Kenyan case-control study (severe malaria) and longitudinal disease cohort study (uncomplicated malaria and asymptomatic parasitaemia) by A) Sl genotypes and …
Parasite isolates were collected from 167 malaria patients in Mali and matured in culture for 18–36 hr before assessment of rosette frequency (percentage of infected erythrocytes forming rosettes …
Clinical outcome | Sl2 aORs (95% CI)* | P value | McCb aORs (95% CI) | P value |
---|---|---|---|---|
All severe malaria† (n = 1716) | 0.78 (0.64–0.95) | 0.011 | 1.10 (0.97–1.25) | 0.108 |
CM§ (n = 943) | 0.67 (0.52–0.87)‡ | 0.006 | 1.19 (1.02–1.38) | 0.025 |
Severe without CM (n = 674) | 1.00 (0.76–1.30) | 0.994 | 0.98 (0.82–1.17) | 0.811 |
Died (n = 180)† | 0.50 (0.30–0.80)‡ | 0.002 | 1.31 (0.95–1.72) | 0.086 |
Died with CM (n = 131) | 0.44 (0.23–0.78)‡ | 0.007 | 1.34 (0.94–1.88) | 0.104 |
Died without CM (n = 42) | 0.73 (0.18–2.30) | 0.636 | 1.00 (0.48–1.94) | 0.940 |
SMA# (n = 483) | 0.76 (0.55–1.05) | 0.099 | 0.96 (0.78–1.17) | 0.688 |
SMA without CM (n = 223) | 0.82 (0.51–1.26) | 0.366 | 0.91 (0.67–1.20) | 0.553 |
Died with SMA¶ (n = 56) | 0.65 (0.21–1.67) | 0.374 | 1.35 (0.77–2.20) | 0.229 |
RD** (n = 522) | 0.81 (0.59–1.10) | 0.181 | 1.12 (0.92–1.35) | 0.225 |
RD without CM (n = 192) | 1.06 (0.66–1.68) | 0.805 | 1.07 (0.80–1.43) | 0.615 |
Died with RD†† (n = 73) | 0.39 (0.14–0.88)‡ | 0.027 | 1.01 (0.59–1.61) | 0.948 |
*Adjusted Odds Ratios (aOR) and 95% Confidence Intervals (CI) are presented for the Sl2 genotype in the recessive form (i.e. Sl2/Sl2 vs all other Sl genotypes) and McCb genotype in the additive form (i.e. change in aOR with each additional McCb allele). Sl and McC genotype were included together in a statistical model to examine their associations with malaria susceptibility. aORs displayed are adjusted for ethnicity, location of residence, sickle cell genotype, α+thalassaemia genotype and ABO blood group. An interaction term between Sl genotype and α+thalassaemia was included in the model. Model outputs following 2000 bootstrapped iterations are shown.
†99 children (7 of whom died) were severe malaria cases whose CM status was not recorded, hence these children are included in the numbers for ‘All severe malaria’ and ‘Died’ but not in ‘with CM’ or ‘without CM’ categories.
‡Models that showed significant evidence of interaction between Sl2 and α+thalassaemia.
§CM, cerebral malaria (P. falciparum infection with a Blantyre coma score of < 3).
#SMA, severe malarial anaemia (P. falciparum infection with Hb < 5 g/dl).
¶34/56 cases who died with SMA also had CM.
**RD, respiratory distress (P. falciparum infection with abnormally deep breathing).
††56/73 cases who died with RD also had CM.
Clinical Outcomes | Sl2 aIRRs† (95% CI) | P value | McCb aIRRs (95% CI) | P value |
---|---|---|---|---|
Uncomplicated malaria | 0.49 (0.34–0.72)‡ | <0.001 4 | 1.24 (0.90–1.70) | 0.184 1 |
All non-malaria clinical visits | 1.13 (0.96–1.32) | 0.140 1 | 0.76 (0.61–0.96)‡ | 0.020 4 |
LRTI§ | 1.09 (0.81–1.47) | 0.561 1 | 0.39 (0.16–0.96) | 0.040 1 |
URTI# | 1.21 (0.98–1.50) | 0.073 1 | 0.79 (0.63–0.99) | 0.047 3 |
Gastroenteritis | 0.66 (0.43–1.03) | 0.066 2 | 0.55 (0.31–0.97)‡ | 0.038 2 |
Skin infection | 1.33 (0.79–2.26) | 0.285 2 | 0.42 (0.16–1.13) | 0.086 1 |
Helminth infection | 1.98 (0.83–4.71) | 0.122 2 | 0.68 (0.43–1.07) | 0.094 4 |
Malaria negative fever | 0.83 (0.58–1.18) | 0.293 2 | 1.03 (0.80–1.33) | 0.828 3 |
*Data were collected from 22 Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 cyfu (child-years of follow-up), respectively, and 137 McCa/McCa, 63 McCa/McCb and 8 McCb/McCb individuals during 294.5, 143.2 and 14.3 cyfu, respectively. Both Sl2 and McCb alleles were tested for their association with the disease outcomes of interest using Poisson regression in the 1recessive, 2dominant, 3heterozygous and 4additive models. The best fitting models as examined using the Akaike information criterion (AIC) were used in the final analysis that included adjustment for McC genotype (for Sl analyses), Sl genotype (for McC analyses) α+thalassaemia and sickle cell genotype, ABO blood group, season (divided into 3 monthly blocks), ethnicity, age as a continuous variable and within-person clustering of events.
†aIRRs: adjusted Incidence Rate Ratios.
‡Models that showed significant evidence of interaction between either Sl2 or McCb and α+thalassaemia.
§LRTI: Lower Respiratory Tract Infection.
#URTI: Upper Respiratory Tract Infection.
Sl1/Sl1 | Sl1/Sl2 | Sl2/Sl2 | ||||
---|---|---|---|---|---|---|
Number of episodes | Incidence | Number of episodes | Incidence | Number of episodes | Incidence | |
All samples | 124 | 2.51 | 493 | 2.31 | 461 | 2.44 |
Normal α globin | 73 | 4.18 | 238 | 2.87 | 77 | 1.64 |
Heterozygous α+thalassaemia | 32 | 1.58 | 209 | 1.92 | 302 | 2.88 |
Homozygous α+thalassaemia | 19 | 1.63 | 46 | 2.09 | 82 | 2.20 |
Incidence = number of episodes per child-year of follow up (cyfu). Data were collected from 22 Sl1/Sl1, 94 Sl1/Sl2 and 92 Sl2/Sl2 individuals during 49.4, 213.8 and 188.8 child-years of follow-up, respectively.
Controls (Uncomplicated malaria) | Cases (Cerebral malaria) | P value | |
---|---|---|---|
Mali | n = 184 | n = 34 | |
Gender Males Females | 90 (49 %) 94 (51 %) | 17 (50 %) 17 (50 %) | 0.920 |
Ethnicity Dogon Non-Dogon | 161 (87.5 %) 23 (12.5 %) | 30 (88 %) 4 (12 %) | 1 |
Age in months* Median (IQR) | 36.5 (19–56) | 28 (16–41) | 0.026 |
Comparisons performed using Pearson’s χ2 test except *Kruskal Wallis test
Sl1/Sl1 | % | Sl1/Sl2 | % | Sl2/Sl2 | % | P value | McCa/McCa | % | McCa/McCb | % | McCb/McCb | % | P value | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Clinical status | Uncomplicated malaria | 19 | 10.3 | 78 | 42.4 | 87 | 47.3 | 103 | 56.0 | 61 | 33.2 | 20 | 10.9 | ||
CM | 5 | 14.7 | 19 | 55.9 | 10 | 29.4 | 0.135# | 16 | 47.1 | 15 | 44.1 | 3 | 8.8 | 0.478# | |
Gender | M | 11 | 10.3 | 48 | 44.9 | 48 | 44.9 | 57 | 53.3 | 41 | 38.3 | 9 | 8.4 | ||
F | 13 | 11.7 | 49 | 44.1 | 49 | 44.1 | 0.945 | 62 | 55.9 | 35 | 31.5 | 14 | 12.6 | 0.430 | |
Ethnicity | Dogon | 21 | 11.0 | 88 | 46.1 | 82 | 42.9 | 108 | 56.5 | 66 | 34.6 | 17 | 8.9 | ||
Non-Dogon | 3 | 11.1 | 9 | 33.3 | 15 | 55.6 | 0.448# | 11 | 40.7 | 10 | 37.0 | 6 | 22.2 | 0.078 | |
Blood group | O | 13 | 10.0 | 63 | 48.5 | 54 | 41.5 | 68 | 52.3 | 49 | 37.7 | 13 | 10.0 | ||
Non-O | 11 | 12.5 | 34 | 38.6 | 43 | 48.9 | 0.355 | 51 | 58.0 | 27 | 30.7 | 10 | 11.4 | 0.566 | |
Median age | Months | 32 | IQR 20–57.5 | 31 | IQR 18–52 | 30 | IQR 17–55 | 0.927 | 30 | IQR 17–52.5 | 31 | IQR 18–54.5 | 51 | IQR 29–64.5 | 0.229 |
CM, cerebral malaria; IQR, interquartile range. Significance testing uses uncomplicated malaria as the reference group. Age: Kruskal Wallis test. #: Fisher’s exact test. All other analyses: Pearson’s χ2.
Additional tables.
(A) General characteristics for the Kenyan case-control study. (B) Characteristics for the Kenyan case-control study by Sl and McC genotype. (C) Hardy Weinberg equilibrium calculations for controls in the Kenyan case-control study. (D) Unadjusted odds ratios for clinical outcomes for the Kenyan case-control study. (E) Sl and McC combined genotypes and adjusted odds ratios for cerebral malaria in the Kenyan case-control study. (F) Sl and McC combined genotypes and adjusted odds ratio for death in the Kenyan case-control study. (G) General characteristics of the Kenyan longitudinal cohort study population by Sl and McC genotypes. (H) Incidence of common childhood diseases by Sl genotypes in the Kenyan longitudinal cohort study. (I) Incidence of common childhood diseases by McC genotypes in the Kenyan longitudinal cohort study. (J) Unadjusted Incidence Rate Ratios (IRR) for uncomplicated malaria and non-malarial diseases in the Kenyan longitudinal cohort study by Sl and McC genotype. (K) Reanalysis of Kenyan case-control study including children who lived outside of the KHDSS study area. (L) Adjusted Odds Ratios for different genetic models for the Sl polymorphism in the Kenyan case-control study. (M) Adjusted Odds Ratios for different genetic models for the McC polymorphism in the Kenyan case-control study. (N) Investigation of the sickle trait/α+thalassaemia negative epistatic interaction and the Sl2/α+thalassaemia interaction by clinical outcome in the Kenyan case-control study. (O) Reanalysis of the Kenyan case-control study excluding all children with one or more sickle cell alleles. (P) Raw data for the combined sickle trait, α+thalassaemia and Sl genotype by clinical outcome in the Kenyan case-control study. (Q) Correlations between the sickle cell, α + thalassaemia, Sl2 and McCb variants in the Kenyan case-control study. (R) Adjusted incidence Rate Ratios (IRRs) for Sl disease associations in the longitudinal cohort study by genetic models of inheritance (S) Adjusted incidence rate ratios for McC disease associations in the longitudinal cohort study by genetic models of inheritance